中国医师进修杂志
中國醫師進脩雜誌
중국의사진수잡지
CHINESE JOURNAL OF POSTGRADUATES OF MEDICINE
2013年
16期
19-21
,共3页
结核,胸膜%糖皮质激素%癌抗原125
結覈,胸膜%糖皮質激素%癌抗原125
결핵,흉막%당피질격소%암항원125
Tuberculosis,pleural%Glucocorticoids%Cancer antigen 125
目的 探讨糖皮质激素治疗结核性胸膜炎的疗效及其对血清癌抗原125水平的影响,以期为结核性胸膜炎治疗提供理论依据.方法 160例结核性胸膜炎患者按随机数字表法分为治疗组和对照组,每组80例,两组均给予抗结核药物治疗,治疗组在此基础上给予泼尼松口服,观察两组患者临床疗效及血清癌抗原125水平变化情况.结果 治疗组显效37例,有效35例,无效8例,对照组显效16例,有效45例,无效19例,两组疗效比较差异有统计学意义(P＜0.05).治疗组患者发热消退时间、胸腔积液消退时间、胸腔积液抽取量及胸膜肥厚发生率明显优于对照组[(9.16±3.74)d比(15.54±0.97)d、(11.78±3.86)d比(16.78±3.50)d、(2345.64±321.75)ml比(3549.03±434.86) ml、40.00％(32/80)比80.00％(64/80)],差异有统计学意义(P＜0.05).两组患者治疗前血清癌抗原125水平比较差异无统计学意义(P＞0.05),治疗组患者治疗后7、14、30d血清癌抗原125水平明显低于对照组[(268.78±93.86) μg/L比(385.78±143.43)μg/L、(159.64±31.96) μg/L比(255.03±44.56)μg/L、(45.34±12.94) μg/L比(167.75±32.76) μg/L],差异有统计学意义(P＜0.05).结论 糖皮质激素治疗结核性胸膜炎临床疗效确切,能早期改善临床症状,值得临床推广应用.
目的 探討糖皮質激素治療結覈性胸膜炎的療效及其對血清癌抗原125水平的影響,以期為結覈性胸膜炎治療提供理論依據.方法 160例結覈性胸膜炎患者按隨機數字錶法分為治療組和對照組,每組80例,兩組均給予抗結覈藥物治療,治療組在此基礎上給予潑尼鬆口服,觀察兩組患者臨床療效及血清癌抗原125水平變化情況.結果 治療組顯效37例,有效35例,無效8例,對照組顯效16例,有效45例,無效19例,兩組療效比較差異有統計學意義(P＜0.05).治療組患者髮熱消退時間、胸腔積液消退時間、胸腔積液抽取量及胸膜肥厚髮生率明顯優于對照組[(9.16±3.74)d比(15.54±0.97)d、(11.78±3.86)d比(16.78±3.50)d、(2345.64±321.75)ml比(3549.03±434.86) ml、40.00％(32/80)比80.00％(64/80)],差異有統計學意義(P＜0.05).兩組患者治療前血清癌抗原125水平比較差異無統計學意義(P＞0.05),治療組患者治療後7、14、30d血清癌抗原125水平明顯低于對照組[(268.78±93.86) μg/L比(385.78±143.43)μg/L、(159.64±31.96) μg/L比(255.03±44.56)μg/L、(45.34±12.94) μg/L比(167.75±32.76) μg/L],差異有統計學意義(P＜0.05).結論 糖皮質激素治療結覈性胸膜炎臨床療效確切,能早期改善臨床癥狀,值得臨床推廣應用.
목적 탐토당피질격소치료결핵성흉막염적료효급기대혈청암항원125수평적영향,이기위결핵성흉막염치료제공이론의거.방법 160례결핵성흉막염환자안수궤수자표법분위치료조화대조조,매조80례,량조균급여항결핵약물치료,치료조재차기출상급여발니송구복,관찰량조환자림상료효급혈청암항원125수평변화정황.결과 치료조현효37례,유효35례,무효8례,대조조현효16례,유효45례,무효19례,량조료효비교차이유통계학의의(P＜0.05).치료조환자발열소퇴시간、흉강적액소퇴시간、흉강적액추취량급흉막비후발생솔명현우우대조조[(9.16±3.74)d비(15.54±0.97)d、(11.78±3.86)d비(16.78±3.50)d、(2345.64±321.75)ml비(3549.03±434.86) ml、40.00％(32/80)비80.00％(64/80)],차이유통계학의의(P＜0.05).량조환자치료전혈청암항원125수평비교차이무통계학의의(P＞0.05),치료조환자치료후7、14、30d혈청암항원125수평명현저우대조조[(268.78±93.86) μg/L비(385.78±143.43)μg/L、(159.64±31.96) μg/L비(255.03±44.56)μg/L、(45.34±12.94) μg/L비(167.75±32.76) μg/L],차이유통계학의의(P＜0.05).결론 당피질격소치료결핵성흉막염림상료효학절,능조기개선림상증상,치득림상추엄응용.
Objective To investigate the effects of glucocorticoid in patients with tuberculous pleuritis and its impact on the level of serum cancer antigen 125 to provide theoretical basis for the treatment of tuberculous pleuritis.Methods One hundred and sixty patients with tuberculous pleuritis were divided into treatment group and control group with 80 cases each by random digits table method.The patients in two groups were given anti-TB medication,and the treatment group was given oral prednisone on the basis of anti-TB medication.The clinical efficacy and serum cancer antigen 125 level change was observed.Results Thirty-seven cases had excellent effect,35 cases showed good effect,and 8 cases was invalid in treatment group and there were 16,45 and 19 cases in control group respectively,and there was significant difference between two groups(P ＜ 0.05).The fever subsidence time,pleural effusion subsidence time,pleural effusion drawing volume,and thickening of pleura in treatment group was less than that in control group [(9.16 ±3.74) d vs.(15.54 ± 0.97) d,(11.78 ± 3.86) d vs.(16.78 ± 3.50) d,(2345.64 ± 321.75) ml vs.(3549.03 ±434.86) ml,40.00％(32/80) vs.80.00％(64/80)],and there was significant difference (P ＜ 0.05).There was no significant difference in serum cancer antigen 125 before treatment between two groups (P ＞ 0.05).The levels of serum cancer antigen 125 after treatment of 7,14 and 30 d in treatment group was lower than that in control group [(268.78 ± 93.86) μ g/L vs.(385.78 ± 143.43) μ g/L,(159.64 ± 31.96) μg/L vs.(255.03 ± 44.56) μg/L,(45.34 ± 12.94) μg/L vs.(167.75 ± 32.76) μ g/L],and there was significant difference (P ＜ 0.05).Conclusions The clinical efficacy of glucocorticoid in treatment of tuberculous pleuritis can improve the clinical symptoms early.It is worthy of clinical application.
